Physician profile
Robin D Evans
NPI 1154495950
$7,890.20
in general payments reported to CMS, 2019-2025
37 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $644 · 2021: $1,202 · 2022: $1,476 · 2023: $1,508 · 2024: $1,356 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,856 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,856.17 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,157.47 | 2019-2025 | |
| Incyte Corporation | $945.11 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $936.09 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Merz North America, INC. | $876.42 | 2020-2023 | |
| Amgen INC. | $497.18 | 2020-2024 | Otezla |
| Galderma Laboratories, L.P. | $473.34 | 2019-2025 | Nemluvio |
| Almirall LLC | $322.47 | 2020-2024 | Klisyri, Seysara |
| Regeneron Healthcare Solutions, INC. | $254.28 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $214.52 | 2019-2025 | Blu-U, Odomzo |
| Allergan, INC. | $191.50 | 2019-2022 | |
| Pfizer INC. | $165.80 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $157.35 | 2021-2024 | Cabtreo |
| Dermavant Sciences, INC. | $145.62 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $143.70 | 2020-2025 | |
| Vyne Pharmaceuticals INC. | $128.29 | 2020-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $125.96 | 2024-2025 | Sotyktu |
| Verrica Pharmaceuticals INC. | $123.76 | 2023-2025 | Ycanth |
| Dusa Pharmaceuticals, INC. | $113.80 | 2019 | |
| Biofrontera INC. | $110.94 | 2022-2025 | Ameluz |
| Genzyme Corporation | $94.61 | 2020-2023 | |
| Epi Health, LLC | $81.33 | 2021-2022 | |
| Revance Therapeutics, INC. | $72.81 | 2024-2025 | Daxxify |
| Botanix Sb INC | $66.81 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $61.08 | 2021-2023 | |
| Arcutis Biotherapeutics, INC. | $55.40 | 2023-2024 | Zoryve |
| Medtronic Vascular, INC. | $52.26 | 2019-2020 | |
| Solta Medical, A Division of Bausch Health US, LLC | $47.25 | 2021-2024 | |
| Lilly USA, LLC | $46.62 | 2024 | Taltz, Olumiant, Ebglyss |
| Journey Medical Corporation | $33.69 | 2022-2023 | |
| Leo Pharma INC. | $33.52 | 2019 | |
| Tepha INC | $29.49 | 2019 | |
| Aclaris Therapeutics, INC. | $26.48 | 2019 | |
| Paratek Pharmaceuticals, INC. | $23.17 | 2024 | Nuzyra |
| Organon LLC | $23.06 | 2025 | Vtama |
| Lnhc, INC | $22.62 | 2025 | Zelsuvmi |
| Sebela Pharmaceuticals INC. | $19.93 | 2023 | Naftin, Pramosone |
| Celgene Corporation | $16.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.